Warwick spin-out NanoSyrinx appoints Dr Jane Dancer as Non-Exec Director.
NanoSyrinx strengthens board with appointment of Dr Jane Dancer as Non-Executive Director.
NanoSyrinx – a spinout from MICRA partner the University of Warwick – announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. NanoSyrinx is an early-stage biotechnology company using synthetic biology approaches to develop a completely novel platform for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans.
Dr Dancer is a highly experienced business leader with previous roles including Chief Business Officer at F-star, Vice President of Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane holds an MA and Ph.D. in Natural Sciences from the University of Cambridge and an MBA from The Cambridge Judge Business School. She has an active role in advising companies on business development and strategy and is currently on the board of Spirea, PharmEnable, Macomics and Chair of the Sir Richard Stapley Educational Trust.
Dr Joe Healey, CEO of NanoSyrinx, commented, “We’re delighted to welcome Jane to our board as Non-Executive Director. Her wealth of experience in business development and company growth will provide valuable insights to guide and support our growth plans and drive the development of our innovative platform technology. I look forward to working with Jane and benefiting from her extensive knowledge.”
NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene editing enzymes and nucleases – directly to the cytosol of targeted cells. The system was first identified by the Waterfield Lab based at Warwick Medical School at the University of Warwick. NanoSyrinx Ltd was founded in 2020 following the completion of an extensive international market validation exercise under the ICURe programme, funded by Innovate UK. In September 2020, the Company announced a pre-seed funding round led by M Ventures with contributions from BioCity and UK Innovation & Science Seed Fund (UKI2S).